Limits...
Importance of lipid accumulation product index as a marker of CVD risk in PCOS women.

Nascimento JX, Chein MB, de Sousa RM, Ferreira Ados S, Navarro PA, Brito LM - Lipids Health Dis (2015)

Bottom Line: There is a paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development of cardiovascular disease (CVD).Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Maranhão, São Luís, Maranhão, Brazil. joelmaximenes@yahoo.com.br.

ABSTRACT

Background: The polycystic ovary syndrome (PCOS) is considered the most common endocrine disease during the woman's reproductive life, with prevalence ranging from 5 to 10% of women of reproductive age. There is a paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development of cardiovascular disease (CVD).

Methods: A cross-sectional study was conducted on 78 women aged 18 to 42 years seen at University Hospital of Maranhão, with a diagnosis of polycystic ovary syndrome according to the Rotterdam criteria. The following variables of interest were recorded on a protocol form: sociodemographic and behavioral data, body mass index, waist circumference, fasting glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol, high-density lipoprotein cholesterol, and systolic and diastolic blood pressure.

Results: Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.

Conclusion: The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome.

No MeSH data available.


Related in: MedlinePlus

Distribution of lipid accumulation product (LAP index) values on the ROC curve of the sample. Lipid accumulation product
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4482191&req=5

Fig1: Distribution of lipid accumulation product (LAP index) values on the ROC curve of the sample. Lipid accumulation product

Mentions: Considering the trade-off between specificity and sensitivity, the cut off point for the LAP index was ≥ 37.9 cm.mmol/L (sensitivity: 85.19 %, specificity: 81.35 %), corresponding to the value closer to 1.0 (best cutoff point), Fig. 1.Fig. 1


Importance of lipid accumulation product index as a marker of CVD risk in PCOS women.

Nascimento JX, Chein MB, de Sousa RM, Ferreira Ados S, Navarro PA, Brito LM - Lipids Health Dis (2015)

Distribution of lipid accumulation product (LAP index) values on the ROC curve of the sample. Lipid accumulation product
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4482191&req=5

Fig1: Distribution of lipid accumulation product (LAP index) values on the ROC curve of the sample. Lipid accumulation product
Mentions: Considering the trade-off between specificity and sensitivity, the cut off point for the LAP index was ≥ 37.9 cm.mmol/L (sensitivity: 85.19 %, specificity: 81.35 %), corresponding to the value closer to 1.0 (best cutoff point), Fig. 1.Fig. 1

Bottom Line: There is a paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development of cardiovascular disease (CVD).Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Maranhão, São Luís, Maranhão, Brazil. joelmaximenes@yahoo.com.br.

ABSTRACT

Background: The polycystic ovary syndrome (PCOS) is considered the most common endocrine disease during the woman's reproductive life, with prevalence ranging from 5 to 10% of women of reproductive age. There is a paucity of studies regarding the use of the lipid accumulation product (LAP) as a risk marker for the development of cardiovascular disease (CVD).

Methods: A cross-sectional study was conducted on 78 women aged 18 to 42 years seen at University Hospital of Maranhão, with a diagnosis of polycystic ovary syndrome according to the Rotterdam criteria. The following variables of interest were recorded on a protocol form: sociodemographic and behavioral data, body mass index, waist circumference, fasting glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol, high-density lipoprotein cholesterol, and systolic and diastolic blood pressure.

Results: Logistic regression showed that, except for HDL, all cardiovascular risk markers presented a higher chance of being altered when the lipid accumulation product was above the cut off value of 37.9 cm.mmol/L.

Conclusion: The lipid accumulation product seems to be sufficient to indicate a risk of cardiovascular diseases in women with polycystic ovary syndrome.

No MeSH data available.


Related in: MedlinePlus